Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
- Resource Type
- Source
- Blood. 140:10144-10147
- Subject
Immunology Cell Biology Hematology Biochemistry - Language
- ISSN
- 1528-0020
0006-4971